Millions of Florida women have access to safer psoriatic disease treatments
Thanks to National Psoriasis Foundation efforts and coordinated outreach by patient advocacy groups, roughly 4 million women in Florida have access to safer treatment options for psoriasis and psoriatic arthritis due to a policy reversal by the Blue Cross Blue Shield plan of Florida (Florida Blue).
Previously, Florida Blue stated that being a woman of childbearing age should not prohibit women from first trying (and failing) methotrexate – a policy known as "fail first" – before being able to move on to a biologic drug as a treatment for psoriatic disease. However, the FDA does not recommend that women of childbearing age use methotrexate due to risk of birth defects and other abnormalities.
National Psoriasis Foundation applauds Florida Blue for reversing this policy.
The Psoriasis Foundation works with health insurers, government and individuals to reverse polices that restrict access to care, and to ensure that the full range of necessary treatments are accessible and affordable.
To learn more about the policy reversal, read the National Psoriasis Foundation letter to Florida Blue »
Aug. 11, 2014